Published on 04/12/2025

Implementing FDA’s Three-Stage Lifecycle Approach to Process Validation

1. Introduction – Validation as a Lifecycle, Not a One-Time Event

The FDA’s 2011 guidance redefined validation from a single qualification exercise to a continuous lifecycle process ensuring ongoing manufacturing control.

It consists of three stages — Process Design, Process Performance Qualification (PPQ), and Continued Process Verification (CPV).

This evolution underscores FDA’s commitment to science- and risk-based decision-making.

2. Stage 1: Process Design

Manufacturers must develop a thorough understanding of the process through experiments, risk assessments, and design of experiments (DoE).

Critical Quality Attributes (CQAs) and Critical Process Parameters (CPPs) are identified to establish the control strategy.

Documentation forms the backbone of later regulatory submissions under CTD Module 3.

3. Stage 2: Process Performance Qualification (PPQ)

PPQ demonstrates reproducibility of commercial manufacturing at scale.

FDA expects statistically justified sample sizes and objective acceptance criteria.

Data from PPQ batches support NDA/ANDA filings and serve as baseline for future comparisons.

4. Stage 3: Continued Process Verification (CPV)

CPV ensures that the validated process remains in control over time.

Trending tools, control charts, and periodic review reports identify early drift.

FDA inspectors often request CPV summaries to verify that firms maintain oversight post-approval.

5. Integrating Lifecycle Data and Risk Management

ICH Q10 links